Single dose tinidazole prophylaxis in hysterectomy.

Area of Science:

• Surgical Infectious Disease
• Pharmacology and Therapeutics

Background:

• Surgical site infections (SSIs) are a significant concern in gynecological procedures like hysterectomy.
• Prophylactic antibiotics aim to reduce the incidence of SSIs and associated patient morbidity.

Purpose of the Study:

• To evaluate the efficacy of a single oral dose of tinidazole as a prophylactic agent against infective morbidity in patients undergoing hysterectomy.
• To assess the pharmacokinetic profile of tinidazole in relation to surgical timing and its inhibitory activity against common anaerobes.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted.
• Participants received either a single oral dose of 2g tinidazole or a placebo approximately 12 hours before hysterectomy.
• Infective morbidity rates, serum tinidazole concentrations, and antimicrobial activity were assessed.

Main Results:

• The incidence of infective morbidity was significantly lower in the tinidazole group (1.9%) compared to the placebo group (12.2%) (p = 0.045).
• Mean serum tinidazole concentration at surgery (35 mcg/ml) exceeded the minimum inhibitory concentration for all 95 tested anaerobes.
• Adequate inhibitory serum concentrations were maintained for at least 24 hours post-surgery.

Conclusions:

• Single-dose oral tinidazole is effective in reducing infective morbidity following hysterectomy.
• Tinidazole prophylaxis is a valuable strategy for preventing febrile morbidity in high-risk gynecological surgeries.
• Current hospital policy now includes tinidazole prophylaxis for surgeries involving potential vaginal wall breach.